MDSpire - Summary
Commentary & Perspectives

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Share

Muir and colleagues' commentary in the British Journal of Ophthalmology discusses the associations between semaglutide and ischaemic optic neuropathy, highlighting that males and those on obesity-dose semaglutide have a higher risk. They present mixed evidence on ocular effects related to GLP-1 receptor agonists, including potential protective factors and increased risks, such as neovascular age-related macular degeneration in diabetics. The commentary emphasizes the need for more nuanced safety data due to the growing use of these medications, particularly among younger patients.

Original Source(s)

GLP-1 Eye Effects Raise Questions

  • by Kerri Miller

  • March 24, 2026

Related Content

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026

  • March 24, 2026

  • 6 min
Could NPDR Be Treated Orally?

Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema

  • March 24, 2026

  • 5 min
Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next